Ceribell Inc

Discover how Ceribell’s insider trades, clinical data, and regulatory milestones point to future growth—and what that means for investors and neurologists.

CTO’s rule‑based buy at $2.24 shows confidence in Ceribell’s rapid, wireless EEG system—yet investors weigh its high volatility, negative earnings and payer‑reimbursement risks.